Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03414047 · ClinicalTrials.gov registry record · Phase 2
A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
A Phase 2 study of Ovarian Cancer, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
- 20
- Study locations
NCT03414047: Completed Phase 2 study of Ovarian Cancer, sponsored by Eli Lilly and Company.
NCT03414047 is a Phase 2 study of Ovarian Cancer that has completed, run by Eli Lilly and Company. The registered enrollment target is 172 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03414047, a Phase 2 study of Ovarian Cancer, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of prexasertib in women with platinum-resistant or refractory recurrent ovarian cancer.
Primary Outcome
Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance
Conditions Studied
Interventions
- DRUG Prexasertib
Study Locations (20)
Tennessee
- University of Tennessee Medical Center - Knoxville
- Sarah Cannon Research Institute SCRI - Nashville
- Tennessee Oncology PLLC - Nashville
New South Wales
- Concord Repatriation General Hospital - Concord
- Prince of Wales Hospital - Randwick
- Westmead Hospital - Wentworthville
Queensland
- Royal Brisbane and Womens Hospital - Herston
- Mater Adult Hospital Brisbane - South Brisbane
Arizona
- Arizona Oncology Associates, P.C. - Tucson
California
- Kaiser Permanente Medical Center - Vallejo
Florida
- University of Southern Florida School of Medicine - Gainesville
Massachusetts
- Dana Farber Cancer Institute - Boston
Missouri
- Research Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2018-04-10 |
| Est. Completion | 2020-10-03 |
| Phase | Phase 2 |
What the finished NCT03414047 record still lists
NCT03414047 is an interventional study that assigns participants to a tested intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Prexasertib is the first listed.
NCT03414047 names 20 study sites across 15 states, led by Tennessee, New South Wales, Queensland.
Frequently Asked Questions
What is clinical trial NCT03414047 about?
NCT03414047 is a clinical study titled "A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer". The purpose of this study is to evaluate the efficacy and safety of prexasertib in women with platinum-resistant or refractory recurrent ovarian cancer.
What is the current status of trial NCT03414047?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2018-04-10. Estimated completion is 2020-10-03.
What conditions does trial NCT03414047 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT03414047?
The interventions under investigation include: Prexasertib (DRUG).
Who is sponsoring clinical trial NCT03414047?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03414047 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03414047's enrollment target sits among peer trials
172 110th of 322 higher than 213 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801797 · 172 participants · Phase 2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- NCT04867317 · 172 participants · Phase 3
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
- NCT05357040 · 172 participants · Phase 2
Antidepressant Effects of Nitrous Oxide
- NCT05587517 · 172 participants · Phase 2
A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI